We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Race Is On for Effective Dengue Vaccine.
- Authors
Voelker, Rebecca
- Abstract
The article offers a look at efforts to develop a safe and effective vaccine for dengue as the viruses that cause the disease pose complex challenges in vaccine development. Sanofi Pasteur and GlaxoSmithKline are cited as the leading contenders to develop a live, attenuated tetravalent vaccine licensed for widespread use in endemic regions. First phase 1 tetravalent vaccine trial was conducted by the National Institute of Allergy and Infectious Diseases (NIAID) on July 1, 2010. It is noted that reverse genetics was used by Sanofi Pasteur to develop its tetravalent vaccine.
- Subjects
VACCINES; DRUG development; PREVENTIVE medicine; DENGUE; SANOFI Pasteur SA; GLAXOSMITHKLINE; NATIONAL Institute of Allergy &; Infectious Diseases (U.S.)
- Publication
JAMA: Journal of the American Medical Association, 2010, Vol 304, Issue 13, p1430
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2010.1386